PW-RT 20mg / IGF-1 LR3 1mg Peptide
PW-RT 20mg;
PW-RT 20mg / IGF-1 LR3 1mg Peptide. Retatrutide 20mg vial is a triple receptor agonist studied for its role in metabolism, appetite regulation, and body weight management. Developed by Eli Lilly, Retatrutide has become one of the most discussed compounds in obesity and metabolic research because it targets three separate hormone pathways involved in energy balance and nutrient regulation.
Unlike earlier compounds that focus on a single receptor, Retatrutide interacts with GLP-1, GIP, and glucagon receptors simultaneously. Researchers are particularly interested in how this combined mechanism may influence appetite signalling, energy expenditure, and metabolic adaptation over longer observation periods.
IGF-1 LR3 1mg;
IGF-1 LR3 is a synthetic, longer-acting analog of insulin-like growth factor 1 (IGF-1). The body’s own IGF-1 carries growth signals from the liver to muscle, bone, and other tissues. IGF-1 LR3 is engineered to do the same thing, but for a much longer period of time and without being captured by the proteins that normally limit IGF-1 activity.
Two structural changes drive the difference. The peptide has an arginine in place of glutamic acid at position 3, and an extra 13-amino-acid extension on the front (the N-terminus), making the full chain 83 amino acids instead of native IGF-1’s 70. These modifications cut its affinity for IGF binding proteins and stretch the half-life to roughly 20-30 hours.
There is no oral or topical version of IGF-1 LR3 in research use. The only practical research format is a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water and injected subcutaneously or intramuscularly. This page treats injection as the only route.




Reviews
There are no reviews yet.